Switching From Oral Atypical Antipsychotics to Xanomeline-Trospium

The Phase 4 SWITCH trial: 105 clinically stable outpatients randomized to a 2-week or 4-week taper of their prior antipsychotic, with 8-week discontinuation, PANSS change and adverse events, alongside the expert panel's taper recommendations by drug class.